CD274 and neoplasm: Although the PD-L1+ rate was higher in primary tumor tissues than in metastatic samples (44.0% vs. 35.6%), improved treatment outcome by atezolizumab was observed irrespective of whether tissues were collected from primary or metastatic tumors.